Consortium for HIV/AIDS Vaccine Development

The mission of the Consortium for HIV/AIDS Vaccine Development (CHAVD) is to accelerate the development of a preventative HIV vaccine through state-of-the-art technologies and advanced knowledge in immunological and clinical research, genomics, bioinformatics and proteomics.

Funded by a seven-year cooperative agreement from the National Institutes of Health, the Consortium will conduct multidisciplinary research into immune responses that prevent infection or control the virus in infected individuals. The team will also generate vaccine components to induce such immune responses and provide broad protection against HIV infection.

Led by Scripps Research Professor Dennis Burton, the project includes an international collaboration of scientists at Emory University, Fred Hutchinson Cancer Research Center, International AIDS Vaccine Initiative, Karolinska Institutet (Sweeden), La Jolla Institute for Allergy & Immunology, The Ragon Institute/Massachusetts General Hospital, Massachusetts Institute of Technology/Howard Hughes Medical Institute, The Rockefeller University, Stanford University, University of Montreal (Canada), University of Southampton (UK), University of the Witwatersrand (South Africa), and other Principal Investigators at Scripps Research.